Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    Open Studies | "Sarcoma, Kaposi"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Sarcoma, Kaposi"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Conditions: Kaposi Sarcoma;   Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
2 Unknown  A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
3 Recruiting sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Condition: Skin Kaposi Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Behavioral: Quality-of-Life Assessment;   Biological: Recombinant EphB4-HSA Fusion Protein
4 Recruiting Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Condition: Kaposi Sarcoma
Interventions: Drug: liposomal doxorubicin;   Drug: pomalidomide
5 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
6 Recruiting 124I-FIAU Imaging in EBV and KSHV Associated Cancers
Conditions: Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Kaposi's Sarcoma;   Gastric Cancer;   Nasopharyngeal Cancer
Interventions: Other: FIAU-PET-CT scans;   Other: FIAU-PET-CT scan
7 Recruiting Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Conditions: Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma;   Solid Neoplasm
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
8 Recruiting Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Conditions: HIV;   Kaposi's Sarcoma;   Lymphomas;   Multicentric Castleman's Disease;   Primary Effusion Lymphoma
9 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
10 Recruiting History of the KSHV Inflammatory Cytokine Syndrome (KICS)
Conditions: KSHV Inflammatory Cytokine Syndrome (KICS);   KSHV;   HHV-8
11 Recruiting Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
Conditions: Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
Interventions: Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus
12 Recruiting Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Conditions: Castleman Disease;   Castleman's Disease;   Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine;   Drug: Tocilizumab;   Drug: Valganciclovir (VGC)
13 Recruiting Lymphatic Anomalies Registry
Conditions: Lymphatic Malformation;   Generalized Lymphatic Anomaly (GLA);   Central Conducting Lymphatic Anomaly;   CLOVES Syndrome;   Gorham-Stout Disease ("Disappearing Bone Disease");   Blue Rubber Bleb Nevus Syndrome;   Kaposiform Lymphangiomatosis;   Kaposiform Hemangioendothelioma/Tufted Angioma;   Klippel-Trenaunay Syndrome;   Lymphangiomatosis
14 Recruiting A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Conditions: Kaposiform Hemangioendothelioma (KHE);   Kasabach-Merritt Syndrome;   Tufted Angioma
Interventions: Drug: Vincristine;   Drug: Sirolimus
15 Unknown  Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
16 Not yet recruiting Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Conditions: B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Biological: XmAb13676
17 Unknown  Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
Condition: Cancer
Interventions: Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: assessment of therapy complications;   Procedure: fertility assessment and management;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
18 Recruiting An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: ABC294640

Indicates status has not been verified in more than two years